Best Gastroenterology Companies in England, United Kingdom
The 32 best Gastroenterology companies in England, United Kingdom in 2026, ranked by funding and momentum. Funding, investors, founders, valuation, tech stack and live signals. Top: Quell.
Ranked: Best Gastroenterology companies in England
| # | Company | Disclosed funding | Last round | Employees | Founder | Tech stack | Patents & IP focus | Recent signals |
|---|---|---|---|---|---|---|---|---|
| 1 | Quell Developer of engineered regulatory T cell therapies for immune diseases | $344M | 46 mo ago | 18 | Giovanna Lombardi Co-Founder | TurbopackNode.jsSalesforce+13 | — | — |
| 2 | OMass Therapeutics Developer of therapeutics for immunological and orphan diseases | $166M | 41 mo ago | 36 36 → 78 (+117%) | Carol Robinson Co-Founder | WordPressApple iCloud MailMySQL+21 | 16 patents Small-molecule modulators of MC2R, GPR65 GPCRs and SMO hedgehog targets | — |
| 3 | Redx Pharma Developer of small molecule medicines for fibrotic disease and oncology | $163M | 36 mo ago | 89 | Lisa Anson CEO | WordPressMySQLPHP+20 | 423 patents Small-molecule kinase inhibitors (ROCK, DDR, Wnt) and their solid pharmaceutical forms | — |
| 4 | Sitryx Biotechnology company focused on immunometabolism, developing therapies | $69M | 39 mo ago | 17 | Paul-Peter Tak Co-Founder & Director | Node.jsNext.jsReact+8 | — | — |
| 5 | VHsquared Designs and develops antibodies engineered to be stable in the gastrointestinal (GI) tract. | $58M | 64 mo ago | 8 | Rod Richards CEO | — | 62 patents Therapeutic peptide design and protease‑cleavable linker technologies for drug conjugates | — |
| 6 | Topivert Kinase Inhibitors for inflammations in GI tract and the eye | $40M | 154 mo ago | 4 | — | — | — | — |
| 7 | Ochre Bio Developer of ribonucleic acid therapies for treating chronic liver diseases | $40M | 48 mo ago | 11 | Quin Wills Co-Founder & CEO | WordPressApple iCloud MailGoogle Workspace+26 | — | — |
| 8 | Shift Bioscience Developer of drugs that reprogram mitochondrial (mtDNA) mutations | $29M | 24 mo ago | 3 | Daniel Ives Founder & CEO | WordPressApple iCloud MailGoogle Workspace+23 | 5 patents AI-based temporal property prediction for molecules and mitochondrial DNA variant analysis. | — |
| 9 | Atlantic Healthcare Specialty pharma company that has Phase III programmes targeting gastrointestinal disorders | $24M | 127 mo ago | 12 | — | — | — | — |
| 10 | Medicina Products for enteral feeding and stoma | $10M | 154 mo ago | 22 | Ken Harrison Founder | WordPressMySQLPHP+24 | — | — |
| 11 | Functional Gut Group Developer of a diagnostic test for gut health | $7M | 19 mo ago | 8 | Anthony Hobson Founder | WordPressMySQLPHP+29 | — | — |
| 12 | Cyted Leader in non-endoscopic diagnostics for digestive health, enabling early disease detection and access to… 53Talent top 28%Funding top 33%Patents top 33%Growth top 35% All 9 signals ▾Talenttop 28% Fundingtop 33% Patentstop 33% Growthtop 35% Innovationtop 37% Moattop 46% Techbottom 45% Globalbottom 40% Marketbottom 32% Talent: 3 named leaders on record · 3 C-suite/founder profiles curated Funding: Raised $6.6M across 6 rounds · 6 rounds over 6 yrs (1.0/yr) rank vs industry peers · Fliar Intelligence Index 53/100 | $7M | 14 mo ago | — | Maria Odonovan Co-Founder & CMO | WebflowSalesforceGSAP+15 | 16 patents Endoscopic devices for esophageal cell collection and Barrett's diagnosis | — |
| 13 | Bloomsbury Genetic Therapies Provider of gene therapy commercialization services | $6M | 51 mo ago | 4 | Adrien Lemoine Co-Founder & CEO | — | — | — |
| 14 | Enteral Access Technologies Developer of a device for safe nasogastric tube placement | $5M | 11 mo ago | — | George Gallagher Founder & CEO | — | — | — |
| 15 | Yaqrit Liver dialysis device | $5M | 68 mo ago | 14 | Rajiv Jalan Founder & CSO | — | 21 patents Extracorporeal blood purification devices and TLR4 antagonist therapies for ammonia control | — |
| 16 | 11health Sensor based alerts for ostomy patients | $2M | 134 mo ago | 3 | Adam Bloom Co-Founder | — | — | — |
| 17 | BeamLine Diagnostics Provider of bedside pre-screening technology for cancer | $1M | 113 mo ago | 7 | — | — | 10 patents FTIR spectroscopy for cell sorting and cancer diagnostics using automated analysis | — |
| 18 | Oxford MEStar Developer of novel scaffolds for tissue engineering and stem cell delivery | $930K | 122 mo ago | 8 | Zhanfeng Cui Founder & Chairman | — | — | — |
| 19 | Curileum Discovering and validating novel stem cell targets to regenerate the mucosal barrier and restore health to… | $466K | 91 mo ago | 6 | Jeff Moore Founder & CEO | — | — | — |
| 20 | DiagNodus Developing non-invasive diagnostic test for colorectal disease conditions | $167K | 152 mo ago | 2 | Alexandre Loktionov CEO | — | 12 patents Non‑invasive colorectal mucus sampling and biomarker analysis for gastrointestinal disease detection | — |
| 21 | BioMe Oxford Provider of a gut-sampling device for the diagnostics of gastrointestinal disorders | $33K | 122 mo ago | 4 | — | — | 15 patents Gastro‑intestinal sampling devices for endoscopic diagnostic collection | — |
| 22 | AgPlus Diagnostics Handheld technology platform for disease diagnosis | — | 121 mo ago | 8 | Robert Porter Founder & CTO | — | 11 patents Lateral flow diagnostic test devices and sample carriers for rapid chemical assays. | — |
Top 12 Gastroenterology companies in England
#1
Seed · Liverpool, England · founded 2018$4.6Mraised▾
Developer of a device for safe nasogastric tube placement. The device DoubleCHEK uses pH and CO2 indicators to confirm correct tube position, reducing the risk of misplacement and lung damage. It features a closed system to maintain infection control and is compatible with existing equipment. The system simplifies the process, eliminating the need for pH paper and messy aspiration.
- Nov 2025Seed$657.9K
- May 2025Seed$186.1K
- Apr 2024Seed$473K
- Apr 2023Seed$2.3M
#2
Series B · Cambridge, England · founded 2018$6.6Mraised▾
Cyted Health is a gastrointestinal health company pioneering non-endoscopic diagnostics to detect diseases early and provide access to care for everyone. Their technologies aim to revolutionize diagnostics and improve patient care.
- Sep 2025Series B$43.8M
- Dec 2020Series A$2.9M
- Oct 2020Series A$817.1K
- Aug 2020Series A$2M
#3
Acquired · Manchester, England · founded 2014 · 8 employees$7.4Mraised▾
Developer of a diagnostic test for gut health. The product includes Breath testing for small intestinal bacterial overgrowth, Methane Breath CH4ECK for detecting abnormal methane levels, ZepHr is a reflux monitoring system, Motion testing for oesophageal function disorders, and Lower bowel testing for disorders of the pelvic floor. The company also has inSIGHT Ultima System and BioVIEW acquisition and analysis software.
- Apr 2025PE$7.4M
#4
Seed · Letchworth Garden City, England · founded 2017 · 3 employees$28.6Mraised▾
Developer of drugs that reprogram mitochondrial (mtDNA) mutations. The company is developing novel drug molecules that can treat diseases where mitochondrial DNA (mtDNA) damage is identified. It has identified small drug agonists able to trigger mitochondrial gene shifting by metabolic reprogramming in specific tissues. The company claims that these molecules can treat age-related diseases such as neurodegenerative diseases or coronary heart disease.
- Oct 2024Seed$16M
- Aug 2022Seed$1.1M
- Jun 2022Seed$10.6M
- Feb 2022Seed$297.7K
#5
Acquired · Liverpool, England · founded 2010 · 89 employees$163.5Mraised▾
Developer of small molecule medicines for fibrotic disease and oncology. The company focuses on novel compounds against biologically or clinically validated targets. It has an extensive programme of pre-clinical research focused on Discoidin Domain Receptors. The company’s core strengths are in medicinal chemistry, translational science, and clinical development.
- Oct 2023Post IPO$17.2M
- May 2022Post IPO$42.6M
- Dec 2020Post IPO$34.1M
- Apr 2020Post IPO—
#6
Series B · London, England · founded 2019 · 18 employees$344.2Mraised▾
Developer of engineered regulatory T cell therapies for immune diseases. This clinical-stage organization focuses on modifying a patient's own regulatory T cells to restore immune balance. These therapies aim to address conditions involving autoimmunity, chronic inflammation, and organ transplant rejection by dampening immune responses and preventing tissue damage. The approach utilizes cellular engineering to regulate immune activity and manage severe inflammatory disorders.
- Jan 2023Series B$24.1M
- Mar 2022Series B$57.9M
- Nov 2021Series B$156M
- Dec 2020Series A$34.9M
#7
Series B · Oxford, England · founded 2016 · 36 employees$166.2Mraised▾
Developer of therapeutics for immunological and orphan diseases. The company's technology platform, called OdyssION, allows them to study protein assemblies and the interactions of targets within their native biological ecosystems with high resolution. The company is advancing a pipeline of small molecule therapeutics primarily for immunological and orphan diseases, using genetic and immune signature stratification to select targets with low translation risk.
- May 2023Series B$12.4M
- Apr 2022Series B$100M
- Feb 2020Series A$35.9M
- 2018Series A$17.9M
#8
Series B · Oxford, England · founded 2018 · 17 employees$69Mraised▾
Biotechnology company focused on immunometabolism, developing therapies. The company exploits the link between immune function and metabolism to create first-in-class, disease-modifying drugs aiming for sustained remission. Their science regulates metabolic pathways in immune cells to restore balance disrupted in chronic conditions.
- Jul 2023Series B$39M
- Dec 2022Series A$3.7M
- Sep 2022Series A$11.8K
- Mar 2020Series A$9.6M
#9
Series A · Oxford, England · founded 2019 · 11 employees$39.7Mraised▾
Developer of ribonucleic acid therapies for treating chronic liver diseases. Research activities focus on identifying drug targets through the analysis of human biological data and tissue models. The organization utilizes computational platforms to predict therapeutic outcomes and creates genetic medicines to address liver fibrosis and cirrhosis. These efforts aim to restore organ function and improve patient survival by targeting specific biological pathways involved in disease progression.
- Oct 2022Series A$30M
- Jun 2021Seed$9.6M
- Mar 2020Seed$125K
#10
Deadpooled · Cambridge, England · founded 2010 · 8 employees$58.2Mraised▾
VHsquared designs and develops novel domain antibodies engineered to be stable in the GI tract. Orally administered domain antibody products provide localised targeting of gastrointestinal infectious and immune-mediated diseases.
- Jul 2021Series A$3M
- Jan 2018Series A$11.2M
- Apr 2016Series A$15.7M
- Sep 2015Series A$9.6M
#11
Series A · London, England · founded 2011 · 4 employees$40.3Mraised▾
TopiVert is a clinical-stage company focussed on developing narrow spectrum kinase inhibitors for the treatment of chronic inflammatory diseases of the gastrointestinal tract and the eye. It has 2 lead candidates namely TOP1288, a mitogen-activated protein kinase (p38 MAPK) inhibitor is in phase 1 trials for the treatment of IBD disease ulcerative colitis (UC) and TOP1630, a kinase inhibitor small molecule which has finished preclinical trials for the dry eye disease.
- Dec 2013Series A$27.8M
- Dec 2011Seed$12.5M
#12
Seed · Cambridge, England · founded 2021 · 4 employees$6Mraised▾
Provider of gene therapy commercialization services
- Aug 2022Seed$6M
Funding & investor landscape
Notable founders
Market landscape — 10 sub-themes by coverage
Share of Gastroenterology coverage by sub-theme.
Regulatory-risk over time rising
Funding & growth over time
funding rising · growth rising
Common questions
Riya reads income statements for fun. She covers the real money in a sector — revenue, growth, who actually earns — and never met a vague claim she didn't want a number for.